The Latest

Nyxoah to Release First Quarter 2023 Financial Results on May 16, 2023

Mont-Saint-Guibert, Belgium – May 1, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter of 2023 […]
May 2, 2023

Mont-Saint-Guibert, Belgium – May 1, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter of 2023 on Tuesday, May  16, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

Investors interested in listening to the conference call may do so by registering for a unique personal PIN at the following link: https://edge.media-server.com/mmc/p/imeku8f7. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.nyxoah.com/events.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

GlobeNewswire Distribution ID 1000807406

Total
0
Shares
Share
Tweet
Previous Article

Sandline Global Announces Strategic Partnership With Everlaw for German eDiscovery Market

Next Article

 Bybit Introduces a New Era of Hassle-Free Crypto Lending

Related Posts

‘Secrets of Shape-Shifting Proteins Revealed’: Real-time observation of life at the smallest scale, shows how vibrations are used by proteins to change shapes and functions

Revolutionary atomic-scale imaging has enabled non-destructive real-time observation of biomolecules within a protein in motion, the observation revealed how proteins use multi-frequency vibrations to change their shapes and functions, this new technology aims to revolutionize nothing less than drug development itself, dramatically reducing time and costs; understanding how life functions at the smallest scales can […]

TSE INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Trinseo PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – TSE

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities Trinseo PLC (NYSE: TSE) between May 3, 2021 and March 27, 2023, both dates inclusive (the “Class Period”), of the important June 20, 2023 lead plaintiff deadline in the securities class action commenced by the Firm. SO […]

Curia Collaborates with Corning to Advance Biopharmaceutical Continuous-Flow Development and Manufacturing Programs

Collaboration marks the first global installation of Corning’s G1 production system to support higher-quality API-chemical production using inherently safer flow-chemistry technology ALBANY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced a collaboration with Corning Incorporated to expand and accelerate continuous-flow development and manufacturing programs for […]